Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Seeks FDA OK to Extend Mirena Duration to Six Years

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/21/2019 | 10:59am EST

By Colin Kellaher

Bayer AG (BAYN.XE) on Monday said it filed a supplemental new-drug application with the U.S. Food and Drug Administration seeking to extend the approved duration of its Mirena intrauterine device to six years.

The Leverkusen, Germany, chemical-and-pharmaceutical company said the request is based on results from a phase 3 extension trial evaluating the efficacy and safety of the contraceptive.

Mirena, which in 2000 became the first hormonal intrauterine device cleared for use in the U.S., is currently approved to prevent pregnancy for up to five years.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
11/18MERCK AND : Bayer Drug Vericiguat Meets Primary Endpoint in Phase 3 Study
DJ
11/18BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
11/14BAYER : to Work With Dewpoint Therapeutics to Develop New Therapies
DJ
11/14Unilever Makes Second Change at the Top -- WSJ
DJ
11/13MEDIATION BETWEEN BAYER, PLAINTIFFS : U.S. mediator
RE
11/13Unilever Names Former Maersk CEO as Chairman
DJ
11/13BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
11/11BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
11/10BAYER : Global agreement supports FieldView expansion in Europe and other region..
PU
11/07BAYER : refinances 1.75 billion euro hybrid bond
PU
More news
Financials (EUR)
Sales 2019 44 389 M
EBIT 2019 7 658 M
Net income 2019 2 929 M
Debt 2019 36 647 M
Yield 2019 4,05%
P/E ratio 2019 22,3x
P/E ratio 2020 13,3x
EV / Sales2019 2,30x
EV / Sales2020 2,10x
Capitalization 65 515 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,44  €
Last Close Price 70,25  €
Spread / Highest target 75,1%
Spread / Average Target 14,5%
Spread / Lowest Target -44,8%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG16.00%72 641
JOHNSON & JOHNSON4.56%354 855
ROCHE HOLDING AG21.63%259 443
MERCK AND COMPANY10.10%214 194
PFIZER-14.73%205 980
NOVARTIS19.39%204 533